STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] MultiPlan Corporation Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Claritev Corporation reported that its Executive Vice President and Chief Operating Officer, Jerome Hogge, purchased 5,621 shares of Class A common stock on 08/07/2025 at a weighted average price of $53.5084 (individual trades ranged from $53.26 to $53.56). Following these purchases, Hogge's beneficial ownership increased to 90,023 shares.

The Form 4 notes the price shown is a weighted average for multiple transactions and that the reporting person will provide full breakdowns of the number of shares purchased at each price upon request. No derivative transactions are reported on this form.

Positive
  • Executive insider purchase: EVP/COO Jerome Hogge acquired 5,621 Class A shares.
  • Increased ownership: Beneficial holdings rose to 90,023 shares following the purchases.
  • Transparent pricing disclosure: Weighted average price of $53.5084 with a disclosed trade range of $53.26–$53.56 and offer to provide per-trade breakdowns on request.
  • No derivatives reported: Table II contains no derivative transactions, indicating a direct-equity purchase only.
Negative
  • None.

Insights

TL;DR: Senior executive purchased 5,621 Class A shares, increasing direct ownership to 90,023 shares; signal positive but materiality unclear without stake percentage.

The reported purchase by the EVP/COO is a direct acquisition of common stock at a weighted average of $53.5084, disclosed as multiple trades within a narrow price band. Insider buys by senior officers can signal confidence in the company's outlook; however, assessing market impact requires the issuer's outstanding shares or market capitalization, which are not provided in this Form 4. The disclosure is transparent about pricing and offers further breakdown upon request, which supports clarity for investors.

TL;DR: Form 4 shows clear, compliant disclosure of an insider purchase with weighted-average pricing and an attorney-in-fact signature; no derivatives reported.

The filing identifies the reporting person as the EVP and COO and records a purchase transaction coded as a purchase. The explanatory footnote properly discloses that the reported price is a weighted average of multiple transactions and promises additional detail on request, which aligns with good disclosure practice. The form is signed by an attorney-in-fact, indicating the reporting obligation was executed by an authorized agent. There are no derivative positions disclosed on Table II.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hogge Jerome

(Last) (First) (Middle)
C/O CLARITEV CORPORATION
7900 TYSONS ONE PLACE, SUITE 400

(Street)
MCLEAN VA 22102

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Claritev Corp [ CTEV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock 08/07/2025 P 5,621 A $53.5084(1) 90,023 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $53.26 to $53.56, inclusive. The reporting person undertakes to provide Claritev Corporation, any security holder of Claritev Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
Remarks:
/s/ Kent Bartholomew, attorney-in-fact 08/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Claritev (CTEV) report on this Form 4?

The Form 4 reports that EVP/COO Jerome Hogge purchased 5,621 shares of Class A common stock (transaction code P).

When did the insider transaction occur for Claritev (CTEV)?

The transaction date listed on the Form 4 is 08/07/2025.

At what price were the Claritev (CTEV) shares purchased?

The shares were bought at a weighted average price of $53.5084; individual trades ranged from $53.26 to $53.56.

How many Claritev (CTEV) shares does the reporting person own after the purchase?

After the reported purchases, the reporting person beneficially owned 90,023 shares.

Does the Form 4 show any option or derivative transactions for Claritev (CTEV)?

No. Table II for derivative securities shows no transactions reported in this filing.

Is there additional pricing detail available beyond the weighted average?

Yes. The filer discloses the weighted average and the trade range and states they will provide a per-trade breakdown on request to the company, shareholders, or SEC staff.
Multiplan Corporation

NYSE:MPLN

MPLN Rankings

MPLN Latest News

MPLN Latest SEC Filings

MPLN Stock Data

295.29M
8.53M
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Services-business Services, Nec
US
NEW YORK